We were delighted to catch up with Philippe Bégin (CHU Sainte-Justine, Montréal, Canada) to discuss the use of epicutaneous immunotherapy for peanut allergy.
The abstract entitled ‘Reduction in Severity Following 12 Months of Epicutaneous Immunotherapy for Peanut Allergy‘ (ABSTRACT NUMBER: 342) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- What are the pros and cons of oral immunotherapy and epicutaneous immunotherapy for peanut allergy? (0:13)
- Could you give us a brief overview of the clinical development of epicutaneous immunotherapy for peanut allergy? (3:37)
- What are the future directions of immunotherapy for peanut allergy? (4:41)
Disclosures: Philippe Bégin is the clinical trial investigator for DBV technology products.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Allergy
Andreas Recke, EAACI 2022: Lanadelumab in the Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency
The ENABLE study (ClinicalTrials.gov Identifier: NCT04130191) is an observational study, investigating the effectiveness of lanadelumab in real-life use in patients with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-1NH). touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) to discuss the aims, design and findings from his interim analysis of the […]
Andreas Recke, EAACI 2022: Unmet Needs in the Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency
Hereditary angioedema with C1-inhibitor deficiency (HAE-C1-INH) is a rare disease resulting in unpredictable attacks of swelling under the skin. touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) around the health burden of HAE-C1-INH and the unmet needs in its treatment. The abstract ‘Lanadelumab Treatment Patterns Among Patients With HAE-C1-INH: Interim […]
Ana Maria Giménez-Arnau, EAACI 2022: A Phase 2b Study of Remibrutinib for Chronic Spontaneous Urticaria
Remibrutinib is an oral BTK inhibitor currently being investigated in a phase 2 trial in urticaria. It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) around the safety findings from the long term extension of a phase 2b study of remibrutinib in chronic […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!